A 2019 rule-change by the US medical devices regulator aimed at encouraging innovations targeting insomnia and anxiety is bearing fruit: Neurovalens, a Belfast-based startup that’s been developing technology to deliver non-invasive electrical stimulation of the brain and nervous system for almost a decade, has just had its second head-mounted treatment device cleared by the FDA.

Neurovalens now has two medical devices approved for prescription by doctors in the US — one to treat generalized anxiety disorder (GAD) and another targeting insomnia. Its GAD device was approved just last week. While its device for insomnia received FDA clearance last October. More products are on the way: A device for treating obesity-related cardiometabolic risk, which targets brain messaging that can influence the storage of harmful visceral fat, is next in the pipeline.

CEO Dr Jason McKeown tells TechCrunch it’s hoping to be granted an FDA “de novo” classification for a third non-invasive neurostimulating device — for people diagnosed with obesity — later this year or early next year. It’s also working on another product for PTSD.

A growing number of startups are taking an interest in applying neurostimulation to treat a range of issues and chronic conditions. Issues like chronic pain, depression and anxiety or stress are often poorly handled by resource-strapped traditional healthcare services. While pharmaceutical interventions have their own drawbacks — not least risks related to side-effects. Non-invasive alternatives that are able to demonstrate efficacy and safety could be transformative. They could also work in concert with drugs to dial up interventions. So there’s huge potential, even as the field of non-invasive neurostimulation remains nascent and novel.

Neurovalens has deliberately chosen to focus on selling regulator-cleared medical devices for specific conditions. This pathway requires it to conduct clinical trials to demonstrate significant results for particular use-cases — i.e. rather than going direct to consumers with a marketing pitch comprised of fuzzier ‘well-ness’ promises — but it’s a differentiating strategy, per McKeown. “As a consumer device, we wouldn’t be allowed to make medical claims,” he points out, noting: “So it’s really to differentiate ourselves as bona fide medical treatment for very, very, very specific conditions.”

“In 2019, the FDA actually updated their regulations and specifically called out insomnia and anxiety because they knew that neurotechnology could potentially treat these things. In those two cases, we were actually allowed to do a 510(k) [FDA application]. But the restriction was that we had to do our own clinical trials,” he tells us, explaining the process the first two prescribable products went through.

A 510(k) clearance refer to a type of FDA application where a medical device can be considered substantially similar to an existing device — rather than the more novel “de novo” classification, which future Neurovalens products targeting other conditions (i.e. not anxiety and insomnia) will need to obtain.

“Typically with a 510(k) you don’t need clinical trials — you’re kind of copying someone that’s been there before. Whereas the FDA were like we don’t feel anything that’s come before has provided enough evidence. So we’re asking them to redo their trials. So we then took the guidance in 2019 and actually started then on our own trials. And, as far as I know, we’re the first company globally who has gone through that process with the FDA and got the first approval in that category.”

Consumers in Europe, where regulations differ, are able to contact Neurovalens to purchase devices directly, according to McKeown. But he confirms it is applying for medical device clearances in the UK and EU too — saying it expects to get its first stamp of approval for doctors in Europe to prescribe its insomnia device as a treatment later this year.

Neurovalens’ products take the form of a head-mounted device that applies electrical neurostimulation to the skin behind the ear — directly targeting the vestibular nerve — as a route to stimulate the hypothalamus and associated autonomic nuclei of the brainstem.

The startup says these are areas of the brain responsible for functions like metabolic control, stress response and circadian regulation. The basic theory for how the mechanism works is targeted stimulation can reregulate the brain’s control centers when areas are not functioning normally. (McKeown also says effects can be lasting, with users able to stop regular treatment after noticing positive change and switch to top-up treatments; while it suggests four weeks of initial use to determine individual efficacy.)

It’s worth noting this is a distinct approach to some other neurostimulation startups, such as those applying Transcranial Direct Current Stimulation (TDCS) or magnetic stimulation.

“We are applying the minimum stimulation but it’s extremely specific,” says McKeown, who argues TDCS is less specific as it applies electricity to neurons on the surface of the brain, rather than going via the brainstem.

“We know those nerve fibres carry signal into the deep area of the brain which previously could only be accessed by an implant,” he says. “It’s a bit like sending a signal down a USB cable or something… The cable itself is almost irrelevant as long as the signal gets from one end to the other. So we can start at the surface and push stimulation down the vestibular nerves and we know that activates then neurons in the brainstem.”

The vestibular system is typically associated with balance but McKeown suggests it’s been underestimated — saying it plays a critical role in “overall homeostasis”; helping regulating everything from blood pressure to breathing rate, heart beat or even how much fat the body stores.

Neurovalens is the first company that’s focused on non-invasive direct stimulation of the vestibular nerve, per McKeown. Although he notes there are startups attempting to develop non-invasive stimulation of the vagus nerve — another cranial nerve which links the brain with organs elsewhere in the body and plays a role in regulating various sensory and motor functions. This was an area Neurovalens also looked at but he says they moved away from after deciding it was too unreliable to target stimulation at — given the presence of more soft tissue, muscle etc. (Whereas, basically, the vestibular nerve is easier to get at.)

“Every cranial nerve stimulator is in our kind of seam area,” he adds. “So, in the general space, there are competitors in the non-invasive space, [But] specifically, we don’t know of anyone who has device approval or regulatory approval for an anxiety treatment.”

On Monday, Neurovalens is also announcing a £2.1M ($2.65M) top up to its Series A funding round, with existing investors chipping in to kick off commercializing the new device in the US market. McKeown says they’ll begin the process of raising a Series B directly — they’re targeting around $40M for that round and aiming to close it out by the end of the year.

So far Neurovalens has raised a total of £23.1M in equity funding — from UK-based investors including Wharton Asset Management, IQ Capital, Techstart Ventures, Angel Co Fund, Beltrae Partners, Clarendon Fund Management and British Business Bank.